Sussex Formulary

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Rheumatoid Arthritis High-Cost Drugs Treatment Pathway

Psoratic Arthritis High-Cost Drugs Treatment Pathway

Abatacept

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Adalimumab

Prescribe by Brand { Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator: Humira
Biosimilars: Imraldi, Amgevita, Idacio and Yuflyma

Adalimumab 20mg/0.2ml solution for injection pre-filled syringes

Pack
2 pre-filled disposable injection

Adalimumab 20mg/0.4ml solution for injection pre-filled syringes

Pack
1 pre-filled disposable injection

Adalimumab 40mg/0.4ml solution for injection pre-filled disposable devices

Pack
2 pre-filled disposable injection

Adalimumab 40mg/0.8ml solution for injection pre-filled disposable devices

Pack
2 pre-filled disposable injection

Anakinra

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Approved for treating Still's disease - commissioned by NHSE.

Anakinra 100mg/0.67ml solution for injection pre-filled syringes

Pack
7 pre-filled disposable injection

Apremilast

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Apremilast 10mg tablets

Pack
4 tablet

Apremilast 20mg tablets

Pack
4 tablet

Apremilast 30mg tablets

Pack
19 tablet
56 tablet

Baricitinib

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Bimekizumab

Black Triangle { Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Certolizumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Etanercept

Prescribe by Brand { Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }
Where more than one biologic treatment is suitable, it is the responsibility
of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting
agreements.
Originator - Enbrel
Biosimilars - Benepali; Erelzi

Etanercept 25mg/0.5ml solution for injection pre-filled disposable devices

Pack
4 pre-filled disposable injection

Etanercept 50mg/1ml solution for injection pre-filled disposable devices

Pack
4 pre-filled disposable injection

Filgotinib

Black Triangle { Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Golimumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Guselkumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Hydroxychloroquine

{ Value = Shared Care, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Infliximab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator - Remicade
Biosimilars - Remisima; Flixabi; Inflectra; Zessly

Infliximab 100mg powder for solution for infusion vials

Pack
1 vial

Infliximab 120mg/1ml solution for injection pre-filled disposable devices

Pack
2 pre-filled disposable injection

Leflunomide

{ Value = Shared Care, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Penicillamine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Risankizumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Sarilumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Secukinumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Tocilizumab

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator - RoActemra
Biosmilar - Tyenne

Tocilizumab 80mg/4ml solution for infusion vials

Pack
1 vial

Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices

Pack
4 pre-filled disposable injection

Tocilizumab 200mg/10ml solution for infusion vials

Pack
1 vial

Tocilizumab 400mg/20ml solution for infusion vials

Pack
1 vial

Upadacitinib

{ Value = BLUETEQ, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Ustekinumab

Prescribe by Brand { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.

Originator: Stelara
Biosimilars: Pyzchiva, Steqeyma, Uzpruvo and Wezenla

Ustekinumab 45mg/0.5ml solution for injection pre-filled disposable devices

Pack
1 pre-filled disposable injection

Ustekinumab 90mg/1ml solution for injection pre-filled disposable devices

Pack
1 pre-filled disposable injection